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Résumé en
anglais
A partial response (PR) has been proposed as a surrogate for overall survival in
advanced adrenocortical carcinoma (ACC). The primary endpoint of the study was to
characterize the time until a PR in patients with metastatic ACC treated with a
standard therapy is achieved. Long-term survivors were selected to allow evaluation
of delayed tumor response to mitotane. Records from patients with metastatic ACC
that survived for > 24 months were retrieved. Tumor response was analyzed
according to the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria.
Time until a tumor response, after treatment initiation or therapeutic plasma mitotane
level, was analyzed. Sixty-eight patients were analyzed. The first-line systemic therapy
was mitotane as a monotherapy (M) (n = 57) or cytotoxic polychemotherapy
plus/minus mitotane (PC ± M) (n = 11). The second-line therapy was M (n = 2) or
PC ± M (n = 41). Thirty-two PRs occurred in 30/68 patients (44.1%): this was
obtained for 13 (40.6%) during M and during PC ± M for 19/32 responders (59.4%).
PRs were observed within 6 months of starting M or PC ± M in 76.9 and 94.7% of
responses, respectively, within 6 months of therapeutic plasma mitotane being first
observed in 88.9% of responses with M and in 53.3% of responses with PC ± M. All
PRs (but one) occurred within 1 year after initiating treatment. To conclude, Most
patients with metastatic ACC and long survival times had PRs within the first
6 months of standard systemic therapy, and almost all within the first year. The
absence of response after that period could be considered as a treatment failure.
Maintenance of mitotane therapy in non-responders after 1 year should be questioned
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